Aptamers, a New Therapeutic Opportunity for the Treatment of Multiple Myeloma.

ABSTRACT: Multiple Myeloma (MM) remains an incurable disease due to high relapse rates and fast development of drug resistances. The introduction of monoclonal antibodies (mAb) has caused a paradigm shift in MM treatment, paving the way for targeted approaches with increased efficacy and reduced toxicities. Nevertheless, antibody-based therapies face several difficulties such as high immunogenicity, high production costs and limited conjugation capacity, which we believe could be overcome by the introduction of nucleic acid aptamers. Similar to antibodies, aptamers can bind to their targets with great affinity and specificity. However, their chemical nature reduces their immunogenicity and production costs, while it enables their conjugation to a wide variety of cargoes for their use as delivery age

SUBMITTER: Amundarain A 

PROVIDER: S-EPMC9657029 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature